Phapros Tbk PT (PEHA) - Cash Flow Conversion Efficiency

Latest as of June 2026: 0.094x

Based on the latest financial reports, Phapros Tbk PT (PEHA) has a cash flow conversion efficiency ratio of 0.094x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Rp41.13 Billion ≈ $2.41 Million USD) by net assets (Rp438.24 Billion ≈ $25.68 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see PEHA market cap overview for the company's overall valuation and market capitalisation.

Phapros Tbk PT - Cash Flow Conversion Efficiency Trend (2011–2025)

This chart illustrates how Phapros Tbk PT's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Phapros Tbk PT Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Phapros Tbk PT ranked by their cash flow conversion efficiency. Explore PEHA cash to earnings ratio to measure how well operating cash flow supports reported net income.

Company Cash Flow Conversion Efficiency
Grand Baoxin Auto Group Limited
F:6BA
-0.007x
Petrolympic Ltd
V:PCQ
0.013x
Lifestyle Global Enterprise
TWO:8066
0.102x
Sparc Technologies Ltd
AU:SPN
-0.290x
Global Surfaces Limited
NSE:GSLSU
0.033x
CEKD Bhd
KLSE:0238
0.024x
High Peak Royalties Ltd
AU:HPR
-0.016x
US Copper Corp
V:USCU
-0.153x

Annual Cash Flow Conversion Efficiency for Phapros Tbk PT (2011–2025)

The table below shows the annual cash flow conversion efficiency of Phapros Tbk PT from 2011 to 2025. View PEHA live share price for real-time trading data and today's change.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-12-31 Rp427.47 Billion
≈ $25.05 Million
Rp70.98 Billion
≈ $4.16 Million
0.166x -53.79%
2024-12-31 Rp393.12 Billion
≈ $23.04 Million
Rp141.28 Billion
≈ $8.28 Million
0.359x +2016.64%
2023-12-31 Rp770.33 Billion
≈ $45.14 Million
Rp-14.44 Billion
≈ $-846.35K
-0.019x -151.56%
2022-12-31 Rp771.82 Billion
≈ $45.23 Million
Rp28.07 Billion
≈ $1.64 Million
0.036x -85.81%
2021-12-31 Rp740.98 Billion
≈ $43.42 Million
Rp189.92 Billion
≈ $11.13 Million
0.256x -26.81%
2020-12-31 Rp740.91 Billion
≈ $43.41 Million
Rp259.48 Billion
≈ $15.20 Million
0.350x +11694.31%
2019-12-31 Rp821.61 Billion
≈ $48.14 Million
Rp-2.48 Billion
≈ $-145.42K
-0.003x +96.86%
2018-12-31 Rp789.80 Billion
≈ $46.28 Million
Rp-75.91 Billion
≈ $-4.45 Million
-0.096x -166.07%
2017-12-31 Rp701.39 Billion
≈ $41.10 Million
Rp102.03 Billion
≈ $5.98 Million
0.145x -20.68%
2016-12-31 Rp622.08 Billion
≈ $36.45 Million
Rp114.08 Billion
≈ $6.68 Million
0.183x +17.67%
2015-12-31 Rp449.72 Billion
≈ $26.35 Million
Rp70.09 Billion
≈ $4.11 Million
0.156x -24.29%
2014-12-31 Rp408.25 Billion
≈ $23.92 Million
Rp84.04 Billion
≈ $4.92 Million
0.206x +313.18%
2013-12-31 Rp391.40 Billion
≈ $22.93 Million
Rp19.50 Billion
≈ $1.14 Million
0.050x -67.11%
2012-12-31 Rp375.63 Billion
≈ $22.01 Million
Rp56.90 Billion
≈ $3.33 Million
0.151x +288.78%
2011-12-31 Rp339.17 Billion
≈ $19.87 Million
Rp-27.22 Billion
≈ $-1.59 Million
-0.080x --

About Phapros Tbk PT

JK:PEHA Indonesia Drug Manufacturers - Specialty & Generic
Market Cap
$14.18 Million
Rp241.92 Billion IDR
Market Cap Rank
#26235 Global
#583 in Indonesia
Share Price
Rp288.00
Change (1 day)
-2.04%
52-Week Range
Rp214.00 - Rp384.00
All Time High
Rp2996.89
About

PT Phapros Tbk, together with its subsidiaries, operates in the pharmaceutical industry in Indonesia. The company operates through Ethical; Over the Counter (OTC) Drugs; Generic Drugs Bearing (OCB); and Toll-in segments. It offers OTC drugs, including Antimo Anak, Antimo tablet, Livron B Plex, Becefort Sirop and tablet, Noza, Febrinex, Betafort suspensi, and Hemorogard. The company also provides … Read more